QurientClinical Trials


 

Clinical Trials

Clinical trials are scientific studies designed to evaluate the effectiveness and safety of a new drug by monitoring their effects. Qurient has been conducting clinical trials in various disease indications. Additional information about our clinical trials is available at www.clinicaltrials.gov, which is a resource provided by the U.S. National Library of Medicine. For more information, please contact Qurient Co., Ltd. (+82-31-8060-1600 or clinicaltrial_info@qurient.com).

Pipeline Condition/Disease Phase Link Status Result
Q702 Solid Tumors 1 NCT04648254 Recruiting  
Telacebec, Q203 Healthy volunteers 1 NCT02530710 Completed  
Telacebec, Q203 Healthy volunteers 1 NCT02858973 Completed  
Telacebec, Q203 Pulmonary Tuberculosis 2 NCT03563599 Completed Telacebec (Q203), a New Antituberculosis Agent.
Q301 Atopic Dermatitis 2 NCT02426359 Completed Poster: 2019 AAD annual meeting.
Q301 Atopic Dermatitis 2 NCT03571620 Completed  
Pipeline Q702
Condition/Disease Solid Tumors
Phase 1
Link NCT04648254
Status Recruiting
Result  

Pipline Telacebec, Q203
Condition/Disease Healthy volunteers
Phase 1
Link NCT02530710
Status Completed
Result  

Pipline Telacebec, Q203
Condition/Disease Healthy volunteers
Phase 1
Link NCT02858973
Status Completed
Result  

Pipline Telacebec, Q203
Condition/Disease Pulmonary Tuberculosis
Phase 2
Link NCT03563599
Status Completed
Result Telacebec (Q203),
a New Antituberculosis Agent.

Pipline Q301
Condition/Disease Atopic Dermatitis
Phase 2
Link NCT02426359
Status Completed
Result Poster: 2019 AAD annual meeting.

Pipline Q301
Condition/Disease Atopic Dermatitis
Phase 2
Link NCT03571620
Status Completed
Result  

For more information about clinical trials:

Phone: +82-31-8060-1600, Monday-Friday, 9am - 6pm (KST)
Email:clinicaltrial_info@qurient.com
Web: www.clinicaltrials.gov








information for download file